Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

ofatumumab MeSH Supplementary Concept Data 2025


MeSH Supplementary
ofatumumab
Unique ID
C527517
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C527517
Entry Term(s)
GSK-1841157
GSKI841157
HUMAX-CD20 2F2
HUMAX-CD20, 2F2
HUMAX-CD20-2F2
arzerra
kesimpta
Pharm Action
Antineoplastic Agents
Registry Numbers
M95KG522R0
0
Heading Mapped to
*Antibodies, Monoclonal, Humanized
Frequency
383
Note
an anti-CD20 MAb used as an antineoplastic agent; in phase 1-2 clinical trials
Source
Blood 2008 Feb 1;111(3):1094-100
Indexing Information
Antigens, CD20
Date of Entry
2008/03/24
Revision Date
2021/08/18
ofatumumab Preferred
arzerra Narrower
HUMAX-CD20 2F2 Narrower
GSKI841157 Narrower
kesimpta Narrower
page delivered in 0.005s